Comparison between propofol and total inhalational anaesthesia on cardiovascular outcomes following on-pump cardiac surgery in higher-risk patients: a randomised controlled pilot and feasibility study.


Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
09 May 2024
Historique:
received: 09 02 2024
accepted: 14 04 2024
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 9 5 2024
Statut: epublish

Résumé

Myocardial revascularisation and cardiopulmonary bypass (CPB) can cause ischaemia-reperfusion injury, leading to myocardial and other end-organ damage. Volatile anaesthetics protect the myocardium in experimental studies. However, there is uncertainty about whether this translates into clinical benefits because of the coadministration of propofol and its detrimental effects, restricting myocardial protective processes. In this single-blinded, parallel-group randomised controlled feasibility trial, higher-risk patients undergoing elective coronary artery bypass graft (CABG) surgery with an additive European System for Cardiac Operative Risk Evaluation ≥5 were randomised to receive either propofol or total inhalational anaesthesia as single agents for maintenance of anaesthesia. The primary outcome was the feasibility of recruiting and randomising 50 patients across two cardiac surgical centres, and secondary outcomes included the feasibility of collecting the planned perioperative data, clinically relevant outcomes and assessments of effective patient identification, screening and recruitment. All 50 patients were recruited within 11 months in two centres, allowing for a 13-month hiatus in recruitment due to the COVID-19 pandemic. Overall, 50/108 (46%) of eligible patients were recruited. One patient withdrew before surgery and one patient did not undergo surgery. All but one completed in-hospital and 30-day follow-up. It is feasible to recruit and randomise higher-risk patients undergoing CABG surgery to a study comparing total inhalational and propofol anaesthesia in a timely manner and with high acceptance and completion rates. NCT04039854.

Identifiants

pubmed: 38724266
pii: openhrt-2024-002630
doi: 10.1136/openhrt-2024-002630
pii:
doi:

Substances chimiques

Propofol YI7VU623SF
Anesthetics, Intravenous 0
Anesthetics, Inhalation 0

Banques de données

ClinicalTrials.gov
['NCT04039854']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Multicenter Study Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Benjamin Milne (B)

Department of Anaesthetics and Pain Therapy, King's College Hospital NHS Foundation Trust, London, UK.

Martin John (M)

Department of Anaesthesia, Guy's and St Thomas' Hospitals NHS Trust, London, UK.

Richard Evans (R)

London School of Hygiene and Tropical Medicine, Medical Statistics, 1 Keppel Street, London WC1E 7HT, UK.

Steven Robertson (S)

London School of Hygiene and Tropical Medicine, Medical Statistics, 1 Keppel Street, London WC1E 7HT, UK.

Pádraig Ó Scanaill (P)

Department of Anaesthetics and Pain Therapy, King's College Hospital NHS Foundation Trust, London, UK.

Gavin J Murphy (GJ)

Department of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK.

Giovanni Landoni (G)

Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Michael Marber (M)

School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK.

Tim Clayton (T)

London School of Hygiene and Tropical Medicine, Medical Statistics, 1 Keppel Street, London WC1E 7HT, UK.

Gudrun Kunst (G)

Department of Anaesthetics and Pain Therapy, King's College Hospital NHS Foundation Trust, London, UK gudrun.kunst@kcl.ac.uk.
School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH